[65] IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :

FLEENOR et al.

Serial No

10/510,585

Filed

October 8, 2004

Examiner

NYA

Group Art Unit

1651

Confirmation No.

1893

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date:

Date:____

July 18, 2006

Name:

D. Sue Stockton

Signature

Title

Agents Which Regulate, Inhibit, or Modulate The Activity and/or

Expression of Connective Tissue Growth Factor (CTGF) as a Unique Means to Both Lower Intraocular Pressure and Treat

Glaucomatous Retinopathies/Optic Neuropathies

THIRD SUPPLEMENTARY
INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. 1.56, 1.97, AND 1.98

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants submit the European Search Report as issued in the corresponding European application. The references as cited, are listed on the attached PTO Form 1449. Applicants have not, however, included copies of the foreign patents as they were provided with an Information Disclosure Statement filed January 11, 2006. Copies of the non-patent literature in accordance with 37 CFR 1.98(a)(2), are enclosed. For the Examiner's convenience, a copy of the European Search Report is also enclosed.

Applicant: Fleenor et al. Serial No: 10/510,585

Page 2

Applicants request that the listed patents, articles, and other information be considered during prosecution of this application and that they appear among the "References Cited" on any patent issuing herefrom.

Respectfully submitted,

Bv:

Mark E. Flanigan, Reg. No. 51,681

Phone: (817) 615-5080

Address for Correspondence:

Mark E. Flanigan IP Legal, TB4-8 Alcon Research, Ltd. 6201 South Freeway Fort Worth, Texas 76134-2099

Attorney Docket No.: 2354F US

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO	respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
	Application Number	10/510,585	
PINFORMATION DISCLOSURE	Filing Date	October 8, 2004	
STATEMENT BY APPLICANT	First Named Inventor	FLEENOR	
JUL 2 A 2006	Art Unit	1651	
tuse as many sheets as necessary)	Examiner Name	NYA	
Sheet 1 of 2	Attorney Docket Number	2354 US	
With The County			

THE	معينيد		U. S. PATENT	OCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code ^{2 (# known)}			Figures Appear
	-	US-			
		US-	· · · · · · · · · · · · · · · · · · ·		
		US-			
		US-			
		US-			
		US-	***************************************		
		US-			hade to the state of the state
		1 , 1		1	

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.¹	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	1,
	A1	WO 01/60374 A1	08/23/2001	Centre National de		
	A2	WO 01/70727 A1	09/27/2001	Sanofi-Synthelabo		
	A3	WO 03/027275 A1	04/03/2003	Hellberg et al.		
	1					
	1		••••		***************************************	

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO	Complete if Known		
	Application Number	10/510,585	
INFORMATION DISCLOSURE	Filing Date	October 8, 2004	
STATEMENT BY APPLICANT	First Named Inventor	FLEENOR	
IIII 2 4 200s &	Art Unit	1651	
JUL 2. 4. 2006 & \ (Use as many sheets as necessary)	Examiner Name	NYA	
Sheet 2 of 2	Attorney Docket Number	2354 US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	B1	Lefevre et al., "Involvement of Cyclin-Dependent Kinases in Axotomy Induced Retinal Ganglion Cell Death", The Journal of Comparative Neurology, Vol. 447:72-81, 2002.	/
	B2	Mass et al., "Apoptosis of Central and Peripheral Neurons Can Be Prevented with Cyclin- Dependent Kinase/Mitogen-Activated Protein Kinase Inhibitors", Journal of NeuroChemistry, Vol. 70:1401-1410, 1998.	1
			ļ
	:		
			ļ
			ļ
•••••••			

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.